• Home
  • ABOUT
    • Leadership Team
    • Scientific Group Leaders
    • Alumni
    • Our Philosophy
  • Services
    • Animal Models
    • Translatability & Advanced Technologies
    • Histopathology Services
  • PUBLICATIONS
  • NEWS
  • Contact
REQUEST A QUOTE
  • Home
  • ABOUT
    • Leadership Team
    • Scientific Group Leaders
    • Alumni
    • Our Philosophy
  • Services
    • Services – Animal Models
    • Services – Translatability and Advanced Technologies
    • Histopathology Services
  • Publications
  • News
  • Contact
  • Request A Quote

MatrileX Highlights Preclinical Rigor Strategies in Fibrosis Research at the 9th AFDD Summit

by admin | Dec 3, 2025 | News

At the 9th Antifibrotic Drug Development Summit, Dr. Yanling Zhang presented MatrileX’s research poster, “Back to the Future: Using Clinical Trial Design to Enhance the Utility of Preclinical Testing in Fibrotic Diseases.” The poster highlights strategies to...

Professor Richard E. Gilbert Co-Chairs Key Sessions at the 9th AFDD Summit

by admin | Dec 3, 2025 | News

Boston, MA — November 17–19, 2025 — MatrileX Laboratories participated in the 9th Antifibrotic Drug Development Summit, a leading industry forum bringing together experts across fibrosis biology, translational research, and early clinical development. Co-Chair of...

MatrileX Laboratories Publishes New Study Defining Dose–Response Biology of Ramipril in the Alport COL4A3−/− Mouse Model

by admin | Dec 2, 2025 | News

MatrileX Laboratories is pleased to announce the publication of our new peer-reviewed study, “Dose-dependent effects of the ACE inhibitor, ramipril, on kidney function and structure in the Alport COL4A3−/− mouse.” The study defines, for the first time, the functional...

MatrileX Scientists Publish New Study Establishing Novel Renal Effects of SGLT2 Inhibition

by admin | Dec 2, 2025 | News

MatrileX Laboratories is pleased to highlight the publication of a new peer-reviewed study, “Induction of proximal tubular proliferation and lengthening in response to sodium–glucose cotransporter-2 inhibition in experimental rats.” This work provides mechanistic...

MatrileX demonstrates broad utility of Col4A3 KO model in CKD/DKD

by admin | May 14, 2025 | Uncategorized

« Older Entries

5W10, Li Ka Shing Knowledge Institute
St. Michael’s Hospital, Unity Health Toronto
209 Victoria Street, Toronto
ON M5B 1T8 Canada

ABOUT

Leadership Team
Scientific Group Leaders
Alumni
Our Philosophy

SERVICES

Animal Models
Translatability & Advanced Technologies
Histopathology Services

CONTACT

Contact

Book a consultation